BioCryst Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-65.8M | $-55.1M | $-43.0M | $-45.2M | $-30.1M | $-39.1M | $-56.9M | $-33.9M |
| Depreciation & Amortization | $704.0K | $483.0K | $180.0K | $177.0K | $304.0K | $628.0K | $886.0K | $2.3M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.6M | $8.5M | $9.7M | $10.2M | $4.4M | $4.2M | $4.8M | $6.3M |
| Net Cash from Operating Activities | $-41.1M | $-53.4M | $-13.1M | $-38.6M | $-26.5M | $-37.4M | $-32.3M | $-28.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $328.0K | $5.3M | $5.1M | $106.0K | $30.0K | $113.0K | $55.0K | $325.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-64.6M | $23.3M | $-18.0M | — | $-3.5M | $24.9M | $11.3M | $221.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | $61.0K | $5.0K |
| Net Cash from Financing Activities | $135.7M | $23.3M | $5.5M | — | $30.3M | $17.0M | $23.8M | $831.0K |
| Net Change in Cash | $28.2M | $-6.8M | $-25.6M | $33.4M | $273.0K | $4.4M | $2.8M | $-27.5M |
| Free Cash Flow | $-41.5M | $-58.7M | $-18.2M | $-38.7M | $-26.6M | $-37.5M | $-32.3M | $-28.9M |